# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates Hologic (NASDAQ:HOLX) with a Buy and maintains $90 price target.
Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:HOLX) with a In-Line and raises the price target from $76 t...
CORRECTION: Citigroup analyst Patrick Donnelly upgrades Hologic (NASDAQ:HOLX) from Neutral to Buy and raises the price target f...
Citigroup analyst Patrick Donnelly maintains Hologic (NASDAQ:HOLX) with a Neutral and raises the price target from $80 to $95.
Results From a Large-Scale Prospective Study Investigating Long-Term Anti-Estrogen Therapy Recommendations Published in JNCCN —...
Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of aware...
UBS analyst Elizabeth Garcia maintains Hologic (NASDAQ:HOLX) with a Neutral and raises the price target from $78 to $79.
Raymond James analyst Andrew Cooper maintains Hologic (NASDAQ:HOLX) with a Outperform and raises the price target from $85 t...